CSIMarket Company Name, Ticker, Industry, else..
 
Gyre Therapeutics Inc   (NASDAQ: GYRE)
 
Price: $6.5700 $-0.02 -0.303%
Day's High: $6.639999866485596 Week Perf: -1.65 %
Day's Low: $ 6.47 30 Day Perf: 14.26 %
Volume (M): 41,633 52 Wk High: $ 9.42
Volume (M$): $ 0 52 Wk Avg: $7.29
Open: $6.60 52 Wk Low: $5.44



 Market Capitalization (Millions $) 661
 Shares Outstanding (Millions) 101
 Employees 618
 Revenues (TTM) (Millions $) 119
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 1

Business Description


Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through its subsidiary, Gyre Pharmaceuticals, in China and the United States. Its commercial portfolio includes ETUARY® (pirfenidone) and Etorel® (nintedanib) for pulmonary fibrosis, and Contiva® (avatrombopag) for hematologic conditions associated with chronic liver disease. The company's lead product candidate is Hydronidone, which targets liver fibrosis.


   Company Address: 12730 High Bluff Drive San Diego 92130 CA
   Company Phone Number: 284-0115   Stock Exchange / Ticker: NASDAQ GYRE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Gyre Therapeutics Pioneers New Hope Hydronidones Breakthrough in Liver Fibrosis Treatment

Published Fri, May 23 2025 10:24 AM UTC

In a landmark achievement recently reported by Gyre Therapeutics Inc. (NASDAQ: GYRE), the company s lead candidate, Hydronidone, has successfully met its primary endpoint in a pivotal Phase 3 trial aimed at treating chronic hepatitis B (CHB)-associated liver fibrosis in China. This remarkable finding signals a turning point in the field of liver disease treatment, opening ne...
Clinical Study

Gyre Therapeutics Achieves Milestones with NMPA Clearance for Pirfenidone Clinical Trials and Strategic Leadership Ex...

Published Mon, Mar 31 2025 11:46 AM UTC

Gyre Therapeutics, a pioneering biopharmaceutical company at the forefront of addressing complex medical challenges, has reached significant milestones in its quest for innovative healthcare solutions. In a decisive move, Gyre Therapeutics recently announced that it has received approval from China’s National Medical Products Administration (NMPA) to commence clinical tria...
Clinical Study

Gyre Therapeutics Announces Chinas NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ...

Published Tue, Jul 2 2024 8:05 PM UTC

Gyre Therapeutics Gains NMPA Approval, Marking a Milestone for Treating CLD-Associated Thrombocytopenia in ChinaGyre Therapeutics Announces China s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaGyre Therapeutics, a leading biotechnology company at the forefront of medical innovation, has announced a landmark achievement wi...
Product Service News

Gyre Pharmaceuticals F230 Secures NMPA Approval in China for Treating Pulmonary Arteri...

Published Thu, May 30 2024 8:05 PM UTC

Gyre Pharmaceuticals, a leading global pharmaceutical company, has recently achieved a significant milestone in its quest to combat the debilitating condition of Pulmonary Arterial Hypertension (PAH). The company has received Investigational New Drug (IND) approval from China s National Medical Products Administration (NMPA) to evaluate their groundbreaking drug, F230, in tr...
Clinical Study

Revolutionary Leadership Added to Gyre Therapeutics' Board of Directors with the Appointment of Rodney L. Nussbaum

Published Thu, Mar 21 2024 11:00 AM UTC

In a groundbreaking move, Gyre Therapeutics, a pioneering biotech company dedicated to advancing treatments for neurological disorders, has announced the expansion of its esteemed Board of Directors through the appointment of accomplished industry veteran, Rodney L. Nussbaum. This strategic addition marks a significant milestone for the company as it aims to accelerate its m...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.54
Price to Sales (Expected) -
Price to Book 4.64
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.12
Working Capital Ratio 6.39
Leverage Ratio (MRQ) 0.48
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.22 $
Revenues (TTM) 1.19 $
Cash Flow (TTM) 0.01 $
Cash 0.86 $
Book Value 1.42 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 193,176
Net Income per Employee (TTM) -27,871
Receivable Turnover Ratio (TTM) 4.43
Inventory Turnover Ratio (TTM) 0.65
Asset Turnover Ratio (TTM) 0.7

Profitability Ratios Current
Gross Margin (MRQ) 92.41 %
Operating Margin (MRQ) -49.35 %
Net Margin (MRQ) -49.03 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Gyre Therapeutics Inc's Segments
Product    168.1 % of total Revenue
Contiva    5.95 % of total Revenue
Etorel    3.19 % of total Revenue
Other Products Product Sales    0.11 % of total Revenue
Collaborations    6.59 % of total Revenue
Pharmaceutical Products    177.29 % of total Revenue
Gyre Pharmaceuticals    177.34 % of total Revenue
Gyre    6.59 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.